Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Increased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,106 shares of the biopharmaceutical company’s stock after purchasing an additional 99 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,212,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $37,000. Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $39,000. Finally, Itau Unibanco Holding S.A. acquired a new position in Regeneron Pharmaceuticals in the second quarter worth $42,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $681.58 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The stock has a fifty day moving average price of $741.54 and a 200 day moving average price of $952.59. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10.

Analyst Upgrades and Downgrades

A number of research firms have commented on REGN. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.